Biotech Startup Biotia Secures $9M in Funding

Biotia, a NYC-based provider of clinical metagenomics solutions, has secured $9 million in a financing round.

The round saw backers including Convergent Ventures, DigitalDx Ventures, Cloquet Capital Partners, Continuum Health Ventures, I-Lab Angels, EGB Capital, Leawood Venture Capital, Red Bear Angels, Red Bear Ventures, Tim Barry, Dr. Clive Fields, and others.

The company will use the funding to launch additional diagnostics in women’s health, pursue reimbursement, and expand into orthopedic diagnostics.

What is Biotia?

Biotia develops clinical metagenomics solutions that use pathogen genomics and artificial intelligence to help diagnose infectious diseases.

Read More:Fintech Startup Walapay Secures $4.6M in Seed Funding

Its BIOTIA-ID Urine Test is designed to identify the causes of recurrent and complicated urinary tract infections (UTIs).

The company focuses on helping patients, healthcare providers, and health systems better identify and respond to challenging and chronic infections.

How Much Funding Has Biotia Secured?

Biotia has secured $9 million in its latest financing round.

The company did not disclose its total funding raised or details of previous funding rounds in the provided information.

Who Invested in Biotia’s Funding Round?

The funding round included Convergent Ventures, DigitalDx Ventures, Cloquet Capital Partners, Continuum Health Ventures, I-Lab Angels, EGB Capital, Leawood Venture Capital, Red Bear Angels, Red Bear Ventures, Tim Barry, Dr. Clive Fields, and others.

The company did not identify a lead investor.

Why the Funding Matters

Biotia will use the new funding to launch additional diagnostics focused on women’s health.

The company also plans to pursue reimbursement for its diagnostic solutions and expand into orthopedic diagnostics.

Who founded Biotia?

Biotia was founded in 2016 by Niamh O’Hara and Christopher Mason.

The company is based in New York City and operates a high-complexity, CLIA-certified diagnostic laboratory.

Biotia is a spinout of the Jacobs Technion-Cornell Institute at Cornell Tech.

"This funding enables us to do what matters most: expand advanced diagnostics available for patients suffering from chronic infections who have been failed by standard laboratory methods," said Niamh O'Hara, PhD, CEO and cofounder of Biotia. "We are using this capital to expand our test menu, pursue reimbursement, and get these tools into the hands of clinicians — so that more patients get better and faster answers.

"The esteemed leaders supporting Biotia at this stage are a testament to the importance of what we are building as we work to make clinical metagenomic solutions rapidly accessible for patients," said Chris Mason, PhD, global director and cofounder of Biotia.

Market and Business Growth

Biotia's BIOTIA-ID Urine Test identifies the cause of recurrent and complicated UTIs with 97% sensitivity and 99% specificity, according to the company.

Its partners and collaborators include Mayo Clinic, Hospital for Special Surgery (HSS), and NASA.

The company develops diagnostic and software solutions based on pathogen genomics and artificial intelligence.

What Happens Next?

Biotia plans to expand its diagnostic portfolio, including new solutions in women's health and orthopedics.

The company will also pursue reimbursement and continue developing its clinical metagenomics and AI-based diagnostic technologies.

Read More:Tim Heyl Co-Founded Homeward Bags $120M in Series D Funding